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Abstract
Background: Few studies have examined cognitive functioning of HIV positive patients in sub-
Saharan Africa. It cannot be assumed that HIV positive patients in Africa exhibit the same declines
as patients in high-resource settings, since there are differences that may influence cognitive
functioning including nutrition, history of concomitant disease, and varying HIV strains, among
other possibilities. Part of the difficulty of specifying abnormalities in neuropsychological functioning
among African HIV positive patients is that there are no readily available African normative
databases. The purpose of the current study was to evaluate the pattern of neuropsychological
performance in a sample of HIV positive patients in comparison to HIV negative control subjects
in Uganda.
Methods: The neuropsychological test scores of 110 HIV positive patients (WHO Stage 2, n = 21;
WHO Stage 3, n = 69; WHO Stage 4, n = 20) were contrasted with those of 100 control subjects
on measures of attention/concentration, mental flexibility, learning/memory, and motor
functioning.
Results: Analysis of covariance (ANCOVA) revealed significant group differences on measures of
verbal learning and memory, speed of processing, attention and executive functioning between HIV
seropositive and seronegative subjects.
Conclusion: Ugandan patients with HIV demonstrated relative deficits on measures of verbal
learning and memory, speed of processing, attention, and executive functioning compared to HIV
negative controls. These results from a resource limited region where clades A and D are prevalent
are consistent with previous findings in the developed world where clade B predominates.
Background
Studies done in the developed world in the era prior to
highly active antiretroviral therapy (HAART) have shown
prevalence rates of dementia ranging from 7.3%–27.3%
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high prevalence of HIV in many African countries, very
few studies have examined cognitive functioning in these
patients. It cannot be assumed that HIV positive patients
in Africa exhibit the same declines as patients in high-
resource settings, since there are differences that may
influence cognitive functioning including nutrition, his-
tory of concomitant disease, and varying HIV strains,
among other possibilities.
Cognitive impairments are relatively common in HIV
infection. The most striking picture is of frank dementia.
HIV associated dementia (HAD) afflicts 10–15% of
patients with advanced infection in the United States [3],
but there is also a high incidence of less severe dysfunc-
tion that has been labeled minor cognitive motor dysfunc-
tion (MCMD). HIV-associated cognitive impairment is
found across all disease stages, with increasing rates of
impairment with increasing systemic stage of HIV disease.
The areas most often affected include attention/concen-
tration, learning, executive, information processing speed,
motor, and psychomotor speed; consistent with damage
to subcortical and frontostriatal systems [3-7]. Conse-
quently, HIV+ patients have higher rates of unemploy-
ment [8] and difficulty completing instrumental activities
of daily living [9].
Access to highly active antiretroviral therapy in Sub-Saha-
ran Africa is increasing. HAART can improve neuropsy-
chological performance in individuals with HIV-
associated cognitive impairment in the United States
[10,11], but the effect of HAART on individuals with HIV-
associated cognitive impairment in Sub-Saharan Africa is
largely unknown. As access to AIDS care and highly active
antiretroviral therapy (HAART) increases, greater numbers
of individuals are receiving care at ambulatory HIV clinics
[12]. Studies have shown that HAART can halt the cogni-
tive decline associated with HIV associated dementia, and
in some cases may reverse it [10,11,13].
HIV clade B is found in the United States, Europe, and
Australia where almost all neuropsychological studies
have been completed. In Uganda HIV clades D and A pre-
dominate over clade B [14]. Variations in HIV clade could
lead to different expression of HIV dementia. Both preva-
lence and characterization could be altered. A higher or
lower prevalence of HIV associated dementia could exist
in non B clade endemic areas, due to possible increased
neurotropism. The pattern of neurological and neuropsy-
chological deficits could also be altered in non B clade
endemic areas. If the underlying neuropathological areas
affected are different in non B clade, then the pattern of
functional impairments will change.
The purpose of the current study was to evaluate the pat-
tern of neuropsychological performance in a sample of
HIV positive patients in comparison to HIV negative con-
trol subjects in Uganda.
Methods
This study was reviewed and approved by the local insti-
tutional review board in Uganda prior to study initiation.
Participants: The study took place at two sites in Kampala,
Uganda. HIV+ subjects were seen at the Infectious Disease
Clinic (IDC) at the Mulago Hospital Complex. This clinic
provides care to HIV+ patients at all stages of their illness.
It is partially funded by the Academic Alliance Founda-
tion. HIV- subjects were recruited from the AIDS Informa-
tion Centre (AIC) in Kampala, Uganda. The AIC provides
a voluntary counseling and testing centre for individuals
who wish to know their HIV infection status. The AIC tests
approximately 120 individuals daily of which about 80%
are HIV-. Informed consent was obtained from all subjects
at both sites.
One hundred ten HIV+ (WHO Stage 2, n = 21; WHO Stage
3, n = 69; WHO Stage 4, n = 20) participants were
recruited from the IDC. Eighty-one HIV+ subjects were
recruited using a random clustered sample from attendees
of the IDC. The remaining subjects were recruited for a
pilot study to evaluate the effect of HAART and had CD4
counts < 200. Forty nine of the subjects had a history of
antiretroviral treatment with varying regimens. Exclusion
criteria were: HIV seronegative, less than 18 years of age,
an active or known past CNS opportunistic infection,
fever > 37.5°C, a history of a chronic neurological disor-
der, active psychiatric disorder, alcoholism, physical defi-
cit (e.g., amputation), severe functional impairment
(Karnofsky < 50), or severe medical illness that would
interfere with the ability to perform the study evaluations.
100 HIV- individuals were recruited from the client base
of the AIC. In order to be considered HIV- the individual
had to have a negative HIV ELISA test in the last year. HIV-
subjects were selected to match the mean age and educa-
tion of the randomly selected HIV+ sample. Applicable
exclusion criteria for the HIV+ subjects were used for the
HIV- subjects.
The 110 HIV positive participants had mean age in years
of 36.72 (SD = 8.71) ; education in years of 9.11 (SD =
5.02), and most were female (69.57%). The 100 HIV neg-
ative control participants had mean age in years of 27.48
(SD = 9.14), education in years of 12.08 (SD = 4.05) and
40 percent female.Page 2 of 7
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Given the fact that our research was conducted in the Afri-
can Region, we utilized the World Health Organization's
(WHO) clinical staging and case definition of HIV in
resource-constrained settings. The WHO disease staging
system for HIV Infection was first produced in 1990 and
updated in September 2005 (World Health Organization,
2005). WHO clinical stages are categorized as Stage 1
through Stage 4, and reflect progression from primary HIV
infection to advanced HIV/AIDS. Each stage is defined by
specific clinical conditions or symptoms: In Stage 1, HIV
disease is asymptomatic and not categorized as AIDS. In
Stage 2: minor mucocutaneous manifestations and recur-
rent upper respiratory tract infections are included. In
Stage 3, unexplained chronic diarrhea (longer than a
month), and severe bacterial infections and pulmonary
tuberculosis are included. In Stage 4, diseases used as indi-
cators of AIDS (brain toxoplasmosis, candidiasis of the
esophagus, trachea, bronchi or lungs, and Kaposi's sar-
coma) are included.
Instruments
Data collection included five sections: (1) A sociodemo-
graphic survey, (2) medical history and functional status
survey, (3) subjective neurological symptoms question-
naire, (4) neurological assessment, and a (5) neuropsy-
chological test battery.
The neuropsychological instruments administered to
both HIV+ and HIV- patients were chosen for their cul-
tural independence as well as their sensitivity for detecting
HIV dementia in HIV+ patients [15]. The tests include
assessments in the domains of functioning of Gross motor
(Timed Gait), Fine motor (Grooved pegboard), Executive
Functioning (Color Trails 2), Speed of Processing (Color
Trails 1, Symbol Digit modalities), Verbal Learning/Mem-
ory (WHO-UCLA Auditory Verbal Learning Test), and
Attention/Working Memory (Digit Span, Forward and
Backward).
The WHO-UCLA Auditory Verbal Learning Test is similar
to the Rey Auditory Verbal Learning Test [16,17]. These
tests both measure verbal learning and memory through a
scored immediate and delayed recall of a 15 word list.
While the structure of each test is the same, the words used
in the WHO-UCLA test have been chosen to be universally
recognized objects independent of culture and language
[18]. Color Trails 1 and 2 test an individual's speed of
processing and are designed as cross-cultural variants of
the Trail Making tests [16,18-20].
All the tests had their instructions and content translated
into Luganda. Tests were administered in either Luganda
or English, depending on a formal assessment of the main
language of the subject. Test administrators were fluent in
both languages. Most of the subjects (81% HIV- and 77%
HIV+) were tested in Luganda. An ANCOVA found no dif-
ference for main language, and no significant differences
for main language within HIV groups on the neuropsy-
chological tests when years of education was adjusted for.
Scores for the individual tests were summed then averaged
into a Total z-score. Note that, we multiplied the Timed
Gait, Grooved pegboard, Color Trails 1 & 2, and Symbol
Digit modalities scores by (-1) so that all positive z-scores
scores indicate improvement and negative scores denote a
decline in performance.
Determination of Dementia
Each HIV+ individual had their demographics, past med-
ical history, neurological symptoms, functional status,
neuropsychological test scores and neurological exam
assessed by the primary examiners, an HIV neurologist
and an HIV neuropsychologist in a consensus conference.
Using this information a Memorial Sloan-Kettering
(MSK) AIDS dementia stage score of 0 (MSK normal or no
cognitive impairment), 0.5 (MSK subclinical), and greater
than or equal to 1 (MSK dementia) was assigned to each
HIV+ individual [21]. In order to be given a diagnosis of
HIV AIDS dementia stage (MSK score = 1 or greater), a
patient had to be impaired in two separate neuropsycho-
logical domains, as well as have significant functional
impairment.
Data Analytic Plan
HIV+ subjects were stratified based on MSK AIDS Demen-
tia stage (0, 0.5 and greater than 1.0). To explore differ-
ences on cognitive domains between groups analysis of
variance was utilized. To examine the relationship
between continuous variables of interest Spearman corre-
lations were calculated. Statistical analysis was done in
SAS 9.1.3 (SAS Institute Inc., Cary, NC). Analysis of Cov-
ariance was utilized where appropriate.
Results
Using ANCOVA, there was a significant difference in neu-
ropsychological total z-scores between the HIV seronega-
tives and seropositives (F (2, 209) = 32.36, p < .0001) after
adjusting for differences in education. Similarly, as shown
in Table 1, ANCOVA adjusting for education found signif-
icant differences between HIV-and HIV+ subjects for AVLT
total, AVLT Delayed Recall, Symbol Digit, Color Trails 1,
Color Trails 2, Digit Span Forward and Digit Span Back-
ward. Modified Timed Gait, Grooved Pegboard using the
dominant and nondominant hands did not reach signifi-
cance between HIV- and HIV+ subjects after adjusting for
education.
There were significant differences found in neuropsycho-
logical tests between MSK AIDS Dementia Stage (see Table
2). As expected, as AIDS Dementia Stage increased, poorerPage 3 of 7
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the total z score (p < .0001), AVLT Total (p < .0001),
Delayed Recall (p < .0001), Symbol Digit (p < .0001),
Grooved Pegboard Dominant (p < .001), Nondominant
(p < .005), Timed Gait (p < .0005), Color Trails 1 and 2 (p
< .0001, both), and Digit Span backward (p < .001) and
forward (p < .06). On most neuropsychological tests, post
hoc analysis found that MSK normal group was equiva-
lent to MSK subclinical group, and MSK dementia group
had poorer functioning than both groups. On Symbol
Digit and Color Trails 2, the MSK normal group was sig-
nificantly better than the MSK subclinical group which
was significantly better than those with MSK dementia,
providing the most separation between groups. On Timed
Gait, MSK normal was better than the MSK Subclinical
group, which was equivalent to the MSK mild dementia
group.
Discussion
HIV dementia in clade B occurs in up to 27% of patients
with advanced HIV prior to effective treatment and has
been associated with CNS white matter disease, often
affecting speed of processing and motor functioning. [1-
3]. We have previously reported a cross sectional HIV
dementia rate of 31% in this same group from Uganda
presumably with subtype A and D [22].
Here, we assessed performance between HIV seronegative
controls and HIV seropositives in Uganda where HIV
clades D and A predominate over clade B [14]. Variations
in HIV clade could lead to differences in prevalence rates,
and/or differences in the functional deficit pattern of HIV
Dementia. Increased neurotropism relative to clade B
would lead to a higher prevalence of AIDS Dementia in
non B clade endemic areas, while decreased neurotropism
would result in lower prevalence rates. Similarly, differ-
ences in the underlying neuropathological areas affected
across clades would result in changes in the pattern of
neurological and neuropsychological functional impair-
ments. For example, a greater preference for frontal areas
in one clade, could result in larger deficits in executive
functioning for those affected. Our primary objective was
to characterize the pattern of neuropsychological func-
tioning in this Ugandan cohort.
In Uganda, a setting of predominantly HIV clade D and A
in sub-Saharan Africa, our study found significant group
differences between the HIV seronegatives and HIV serop-
ositives on measures of verbal learning and memory,
speed of processing, attention and executive functioning.
As HIV disease stage progressed, correlations with poorer
verbal learning and memory, speed of processing, atten-
tion/working memory, and executive function were
found. Characterization of neuropsychological perform-
ance across MSK AIDS Dementia Stage found that all tests
were poorer in those with MSK AIDS Dementia compared
to those without. Executive function, Speed of processing,
and Gross Motor functioning were poorer in those with
MSK Subclinical Dementia than those HIV+ individuals
with no evidence of dementia.
HIV+ Ugandans demonstrated a relative decline, in meas-
ures of verbal learning and memory, speed of processing,
attention, and executive functioning compared to HIV
negative controls. This is a similar pattern to what has
been found in the US, Europe and Australian settings, and
would suggest that the pattern of neuropsychological loss
will be the same with clade A and D HIV infection [5,15].
In turn, this would suggest that HIV clade A and D have
the same underlying pattern of neuropathology. There
was no formal assessment of clade in this study. However,
another study found faster systemic progression in clade
D over clade A in Uganda. [23] Given that neuropsycho-
logical deficits are often correlated to immunological def-
Table 1: Descriptives of Neuropsychological Functioning of HIV seronegatives and HIV seropositives.
HIV seropositives HIV seronegatives
Valid N Mean SD Valid N Mean SD F p
AVLT Recall 109 7.25 2.48 100 9.2 2.27 32.63 < .0001
AVLT Total 110 37.25 8.66 100 43.57 7.41 28.81 < .0001
Symbol Digit 105 24.13 11.41 100 31.12 11.27 18.96 < .0001
Pegboard Dom 108 91.58 26.9 100 86.48 21.33 1.19 ns
Pegboard Non 108 102.78 37.52 100 102.71 25.23 0.17 ns
Gait 108 7.21 1.65 98 6.95 0.82 1.2 ns
Trails 1 107 92.67 49.71 99 74.38 22.21 9.65 < .0005
Trails 2 106 166.97 57.67 99 124.51 37.01 33 < .0001
Digit forward 110 4.91 0.89 100 5.28 0.87 7.36 < .005
Digit back 110 2.99 1.1 100 3.47 0.9 8.48 < .001
AVLT = WHO-UCLA Auditory Verbal Learning Test; Dom = Dominant hand; Non = nondominant hand; Gait = Modified Timed Gait; Trails = 
Color Trails; Digit forward = WAISR Digit Span Forward; Digit Back = WAISR Digit Span Backward.Page 4 of 7
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higher deficits in those with clade D compared to clade A
over time.
We found no significant difference in the fine and gross
motor tests between the HIV positive and HIV negative
groups in this setting. However, in this study we found
that both fine and gross motor performance become more
impaired in those with AIDS Dementia, and may be use-
ful in separating those with Subclinical Dementia from
normals. In a separate study using the International HIV
Dementia Scale, (IHDS), a screening test for HIV demen-
tia which evaluates motor and psychomotor speed per-
formance, we have found that motor functioning remains
important in determining AIDS Dementia Stage in these
Ugandan patients [24]. Another study on cognitive func-
tioning in a non-clade B HIV sample has suggested that
other HIV clades are neuropathogenic. Cognitive func-
tioning in individuals infected with clade C in India found
neuropsychological deficits in HIV+ subjects compared to
HIV- subjects [25].
AIDS related neurological disease has a very high cost in
terms of loss of functional ability. Patients have higher
rates of unemployment, decreased ability to perform their
activities of daily living including difficulty completing
such tasks as meal preparation and housework [8,26].
These data suggest that Ugandan patients demonstrate a
relative decline on measures of verbal learning and mem-
ory, speed of processing, attention, and executive func-
tioning compared to HIV negative controls. These deficits
are likely to have an impact on a patient's ability to main-
tain employment outside of the home, or to complete
activities to maintain the household. When this happens,
many others are affected as well. Dependent children or
parents will also experience the losses associated with
these deficits: less income, food and caretaking ability.
Initiation of antiretroviral therapy in these individuals
may reverse some of these neuropsychological deficits,
and allow continued employment and household main-
tenance.
There are noteworthy limitations that should be consid-
ered when interpreting the current study's findings. While
there is a need for neurocognitive assessments in resource
limited settings, our battery was relatively brief, which
may limit its sensitivity to HIV-related neurocognitive
impairment [27]. Further, we suspect that speaking
Luganda is a surrogate marker for multiple factors, such as
lower socioeconomic status, decreased access to health-
care and decreased nutritional status. These factors were
not measured in the current study, but inclusion of these
factors in future work may determine any association with
an increased risk of HIV dementia. Control subjects were
determined by requiring the negative control subjects to
have a negative HIV ELISA in the last year. There is a
chance that some control subjects could have become HIV
positive within that time frame.
Further studies to characterize HIV associated dementia
and neuropsychological functioning in resource limited
settings are necessary. The response of neurological dis-
ease to treatment will also be important to characterize.
These studies will be particularly difficult to engage in, but
can be aided by committed researchers on the ground that
are competent and bring the necessary local experience to
successfully complete them.
Conclusion
The current study found neuropsychological deficits in a
region where clades A and D are prevalent, consistent with
previous findings in the developed world where clade B
predominates. Ugandan patients with HIV demonstrated
deficits on measures of verbal learning and memory,
speed of processing, attention, and executive functioning
compared to HIV negative controls. Fine and gross motor
Table 2: Neurocognitive performance by ADC Stage
0 (Normal) 0.5 (subclinical) 1 (mild)
Mean SD Mean SD Mean SD F p Group difference
Total z 0.30 0.32 -0.29 0.48 -1.26 .78 44.16 0.0001 0 > .5 > 1
AVLT Recall 8.84 1.71 8.14 2.23 5.5 2.06 16.99 0.0001 0 = .5 < 1
AVLT Total 43 5.52 40.7 7.7 33.8 6.18 11.77 0.0001 0 = .5 < 1
Symbol Digit 36.63 7.85 25.77 10.78 17.33 9.81 20.36 0.0001 0 > .5 > 1
Pegboard Dom 78.47 8.44 86.73 21.62 106.2 35.69 7.55 0.001 0 = .5 > 1
Pegboard Non 86.53 9.43 93.97 18.68 122.68 64.06 6.08 0.005 0 = .5 > 1
Gait 6.6 0.71 6.82 0.71 7.64 1.22 8.85 0.0005 0 < .5 = 1
Trails 1 60.47 20.87 81.43 39.08 117.56 52.68 11.35 0.0001 0 = .5 < 1
Trails 2 109.11 23.27 159.77 46.64 216.08 55.56 30.23 0.0001 0 < .5 < 1
Digit forward 5.26 0.99 5.03 0.83 4.64 0.81 2.99 0.06 0 = .5,.5 = 1, 0 < 1
Digit back 3.79 0.85 3.08 1.06 2.64 0.86 7.79 0.001 0 < .5 = 1
ADC Stage is the Memorial Sloan Kettering AIDS Dementia StagingPage 5 of 7
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Dementia. The pattern of neuropsychological deficits
found in this study is similar to what has been found in
the US, Europe, and Australia, suggesting that HIV clades
A and D have the same underlying neuropathology as
clade B. These neuropsychological deficits are likely to
influence the patient's activities of daily living and ability
to maintain employment, although initiation of antiretro-
viral therapy has been shown to improve these deficits in
some.
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